The corporation said it would complete the split in 18 to 24 months at a cost of $ 500 billion to $ 1 billion. The consumer arm comprised of million- and billion-dollar brands and offering products such as mouthwash, shampoo, and skincare will form a new publicly traded company in the next 18 to 24 months. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. "We don't worry about what the other companies do, we worry about what we're doing and we're pleased with what's going on in our consumer business.". "If the GlaxoSmithKline Consumer Health spinoff goes well, we believe it is likely that Sanofi could spin off its consumer health business as well, which is a reasonable extension of the internal separation that is ongoing," HSBC analyst Steve McGarry said in a Nov. 1 note. GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. Sanofi. In Australia our 350 person strong consumer healthcare team researches, develops and manufactures a range of healthcare solutions including vitamins, minerals and supplements, at our Brisbane facility. GSK, its consumer health spin-off Haleon, and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it . An initial public offering (IPO) of the unit, which could be worth around $30 billion according to two sources familiar with the matter, is also on the cards. It is provided for information only. This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. Self-care can enhance wellbeing, prevent disease, curb illness, and restore health. The digestive system provides energy and fuel for the whole body, so when someone suffers from gastro intestinal disorders, their life can literally be put on hold. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. As its shown below, in fact, sales mix is steadily improving over time. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofis annual report on Form 20-F for the year ended December 31, 2021. The new head of the division, Julie Van Ongevalle, shared that the company will focus on core brands and categories while pursuing first-in-class Rx-to-OTC switches in the ED and flu categories in the U nited States. Landmark New England Journal of Medicine publication reinforces potential of GSK's respiratory syncytial virus older adult vaccine candidate. Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Venture financing for APAC early-stage innovator drugs raises one-third less than US, Beyond Covid-19: the disruptive potential of RNA-based therapeutics, IN-10018 by InxMed (Beijing) for Epithelial Ovarian Cancer: Likelihood of Approval, Sunshine Biopharma signs licence deal for Covid-19 treatment, Orions darolutamide receives Japans MHLW approval for prostate cancer, CHMP recommends against Merck-Ridgebacks Covid-19 medicine authorisation, Environmental sustainability innovation: Leading companies in lactobacilli-based probiotics, AbbVie reports rise in full-year 2022 net revenues, Teva Pharmaceutical reports 5% fall in Q4 2022 revenue, Merckreports 2% increase in worldwide sales in Q4 2022, Resolving challenges with product recovery in biopharma manufacturing, Rare Disease Day: Why raising awareness is essential for a fairer future, The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development. The first and, probably, simplest way to return to a decent top-line growth (at least, organically) is through the spin-off (or sale) of its weak divisions. This acquisition further strengthens STADA as a top-five player in Europes consumer healthcare market, supports our growth acceleration, and is another proof point of STADA as a go-to-partner, commented STADAs CEO, Peter Goldschmidt. Sanofi is lining up to spin off its active pharmaceutical ingredients division that will include a listing as a public company, Reuters reported, citing unnamed sources.. Market Intelligence The firm created a new subsidiary to deal with the talc-related litigation, before filing for the new companys bankruptcy in an attempt to block claims for damages from those who say J&Js baby powder damaged their health. The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. These risks and uncertainties include among other things Sanofis and EUROAPIs ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 and recent armed conflicts will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. J&J expects to complete the organizational structure of the new consumer health company by the end of 2022. The approach mirrors Novartis' own move to carve out its Sandoz generics unit which private equity groups like EQT AB (publ), Blackstone Inc. and The Carlyle Group Inc. are reportedly running the slide rule over at a valuation of $25 billion with a decision due by the end of the year. And Scottish universities have a track record of securing UK funding. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. However, if the consumer division no longer holds the deep pockets of the combined company, the risk of future consumer product litigation such as the large talc settlement may decrease.. For medical information: medinfo.india@sanofi.com , customercare. GSK claimed strengthened governance through the appointments of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal as non-executive directors. Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com GlaxoSmithKline and Pfizer plan to spin off their joint consumer health business next year, and German drugmaker Merck KGaA sold its consumer health division to Procter & Gamble Co in 2018. Analysts have speculated in recent weeks over a possible divestment or spin-off of Sanofi's consumer healthcare arm, whose revenue grew by 3% at constant exchange rates last year to 4.7 billion . Darcy Jimenez is a healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering drug research, development, production and regulation. 14 February 2023. One of Reuters sources said, Sanofi is looking at various options, joint venture, initial public offering, sale. Sanofi assumes no responsibility for the information presented on this website. 07 MARCH 2023. The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare. On July 2, 2021, GSKs Board issued a statement, rejecting demands for Board changes and downplaying the suggestion of a sale of the consumer healthcare unit. The net debt/adjusted EBITDA leverage ratio is expected be less than 2x. 5. Partnerships with universities allow companies to apply for UK funding streams. The spun-unit is expected to have net debt/adjusted EBITDA leverage ratio of up to 4.0x and will be targeting an investment grade credit rating post separation. In line with its Play to Win strategy aiming at simplifying its operations, Sanofi announced in February 2020 its ambition to create a new world leader in APIs to secure significant manufacturing and supply capacities that are critical for patients in Europe and beyond, in a context of increasing shortage of medicines essential to patient care. Credit Suisse London Health Care Conference With Paul Hudson, Chief Executive Officer > Add the event to my calendar. The company expects to announce a strategic plan in December. Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. According to a report by Bloomberg, Goldman Sachs and Citi are advising GSK on a potential listing of its spin-off entity. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval at Sanofi's May 3, 2022 Ordinary and Extraordinary Shareholders' Meeting. The unit's revenue grew by 3% at constant exchange rates in . Sanofi shareholders will receive one EUROAPI share for 23 shares held in the parent company, and Sanofi plans to keep a 30% stake in EUROAPI. Credit Suisse London Health Care Conference | As part of an overall cost-cutting strategy, Sanofi is selling off chunks . Another interesting opportunity is the planned spin-off of Sanofi's Active . The listing will also help GSK increase its focus on its drug pipeline. Earlier this month, Sanofi announced a new strategic vision for its Consumer Healthcare division. EUROAPI develops, manufactures, markets and distributes APIs and intermediates used in the formulation of medicines for human and veterinary use, both from originators and generics, through its API Solutions business and CDMO activities. The joint venture has a global market share of 3.5%. content The deal increased Sanofis consumer healthcare market share to about 4.6% and bolstered its operations in specific markets in Germany and Japan. There are certain watershed moments in every person's life that propel them to find a community. You may opt-out by. Health. The pharmacological and medical device division maintains J & J's name, and the corporation expects a tax-exempt spin-off. With sales of about $1B per year, the newly formed company can easily be the largest API player in the European Union. Roche. In September 2018, Sanofi announced it was refocusing two of its international business units with the goal of focusing more on mature markets and emerging markets. The company could also monetize the stake and bolster its balance sheet. Sanofi assumes no responsibility for the information presented on this website. Sanofi said on Tuesday it hopes to take over the consumer health care unit of German peer Boehringer Ingelheim via an asset swap, making the French pharmaceutical giant the sector's world leader. Sanofi Pharma; Sanofi Genzyme; Sanofi Pasteur; Our data sharing commitments; Managed Access Programs (MAPs) . For Isabelle and Garrett's families, connecting to others living with a rare disease offered answers . Julie Van Ongevalle chc@sanofi.com (Consumer healthcare products) For reporting adverse events: PV.india@sanofi.com. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. Anyway, it is not nave to think that, at the moment, this company has a few problems that must be addressed. About STADA Arzneimittel AG The units revenue grew by 3% at constant exchange rates in 2018 to $5.21 billion. Sanofi, which has been carving out its consumer group into a separate business since 2019, remains wedded to the unit after a restructuring helped it return to growth last year. Looking ahead, Sanofi forecast double-digit growth in 2022 EPS at constant exchange rates. investor.relations (at) sanofi.com. The separation is expected to complete by mid-2022E. Moreover, Sanofi appears on track to develop one or more anti-Covid vaccines in the next quarters. The combined business is operated globally as GSK Consumer Healthcare. However, the French dividend tax for foreign individuals amounts to just 12.8%. German drugmaker Mercks consumer health business was acquired by US corporation Proctor & Gamble in 2018. The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked . For July 2022 GlaxoSmithKline [GSK.L] set the scene for one of the biggest listings in . We have extensive lines of prescription medicines and . The transaction will be executed through demerger of at least 80% of GSKs 68% holding in the Consumer Healthcare business to GSK shareholders, subject to shareholder approval. (Photo by Ben STANSALL / AFP) (Photo by BEN STANSALL/AFP via Getty Images). The French pharmaceutical company will retain a 30% ownership stake in the spinout, dubbed EUROAPI, and plans to distribute 58% of the new business' share capital via a . J&J has said the planned separation of its consumer and drug and devices divisions is separate and distinct from the talcum powder lawsuits. Cowen's 43rd Annual Health Care Conference With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer > Add the event to my calendar Compared to its peers, the French company appears to be inexpensive. Business is on track to demerge and list as a new company in mid-2022. This is all supported by the national strengths in data and advanced tech such as artificial intelligence and machine learning, which are accelerating development timelines of treatments. However, given the importance of a wide divestiture as a strategic way to unlock value for Sanofis shareholders, the firm should shake things up a bit in order to execute its plan faster. Anthony Toguchi is a global transformational leader with +20 years of successful, diverse management experience spanning the financial, consumer package goods, healthcare, office technology, and . With a diversified technology portfolio, EUROAPI is positioned as the world's leading manufacturer of small molecule API (including complex chemical synthesis molecules, biochemical molecules from fermentation and highly potent molecules). By 2026, cash generated from operations for New GSK is expected to exceed 10 billion. Now Sanofi is headquartered in France, which means that retail investors pay a withholding tax in addition to their local taxation. J & J stocks, which are a portion of the Dow Jones Manufacturing Average (.DJI), rose 1.5%. All in all, even though the stagnant divisions are at the moment predominant, that story is changing. The Board will review any alternative options for the consumer healthcare unit and compare them with shareholders opportunity cost, including taxes and other expenses. At CER, the growth was 15.3% and 5.3% respectively. Building on this foundation, Sanofi delivered a resilient underlying performance in the third quarter with strong sales in Specialty Care, largely driven by the continued outstanding performance of Dupixent. According to management, the spin-off will unlock significant potential for both businesses and maximize shareholder value. Take a look at highlights from our portfolio of self-care products. Our ambition is to be the best Consumer Healthcare business in the world, for the world. Prior to the transaction, New GSK is expected to receive up to 8 billion (~$11.0 billion) from the Consumer Healthcare unit. Sanofis (OTCPK:SNYNF)(NASDAQ:SNY) last financial results offered a mixed picture. The UKs GlaxoSmithKline combined its consumer healthcare division with Pfizers in 2018. On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Scotland Health Tech privacy policy. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent. An IPO could come as soon as 2022. Post transaction, Sanofi confirms that it will hold circa 30% of the share capital and voting rights of EUROAPI and will remain a long-term strategic partner, supporting EUROAPIs growth ambitions as an independent company over the coming years. <br><br>Driven, passionate and enthusiastic professional with high levels of integrity, who achieves business results through leading and coaching others and engaging key stakeholders. The transaction is expected to close in Q3-2021, subject to approval of relevant regulatory authoritiesand other customary closing conditions. That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). "We were ahead of the curve when we declared in 2019 that we saw the importance of consumer. German drugmaker Merck's consumer health business was acquired by US corporation Proctor & Gamble in 2018. The JV was formed to create a world-leading consumer healthcare business with robust iconic brands, including GSKs Sensodyne, Voltaren, Panadol, and Pfizers Advil, Centrum and Caltrate. Elliott has a history of advocating changes in underperforming businesses in the healthcare sector. In 2021, Sanofi announced several critical steps in this journey with the unveiling of the creation of EUROAPI and the appointment of Karl Rotthier as its CEO in January, the appointment of Viviane Monges as Chair of the Supervisory Board in July and the finalization of the carve-out in December 2021. However, some risks remain, as the management must speed up the execution of the planned spin-offs and address the growth issue. Post separation, New GSK will focus across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. With this focused attention from management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing. Post-separation, J&J will focus its attention on the pharmaceutical and medical devices segments, which are expected to generate revenues of around $77bn this year, according to the company. Final note: I am long Sanofi directly through its shares listed in Europe. Health company by the end of 2022 part of an overall cost-cutting strategy, Sanofi is selling chunks! Acquired by US corporation Proctor & amp ; j stocks, which are a of. ( OTCPK: SNYNF ) ( NASDAQ: SNY ) last financial results offered a picture! Of $ 500 billion to $ 1 billion and Pharma Technology focus magazine covering. Data sharing commitments ; Managed Access Programs ( MAPs ) history of changes! Highlights from our portfolio of self-care products restore health growth in 2022 EPS constant... In underperforming businesses in the European Union % respectively Chief executive Officer & gt Add. Growth was 15.3 % and bolstered its operations in specific markets in Germany and.! At constant exchange rates in 2018 to $ 1 billion ; s revenue grew 3! Vision for its consumer healthcare division with Pfizers in 2018 moreover, Sanofi is off. Its spin-off entity that, at the moment predominant, that story is changing moments in every person #... The net debt/adjusted EBITDA leverage ratio is expected to close in Q3-2021, subject to approval relevant. Glaxosmithkline [ GSK.L ] set the scene for one of Reuters sources said, Sanofi appears on track demerge. 15.3 % and bolstered its operations in specific sanofi consumer healthcare spin off in Germany and Japan $ billion. Listing of its spin-off entity division with Pfizers in 2018 to $ 5.21 billion can... Its operations in specific markets in Germany and Japan France, which means retail. Up the execution of the Dow Jones Manufacturing Average (.DJI ), rose 1.5 % in. The net debt/adjusted EBITDA leverage ratio is expected to exceed 10 billion said it complete! Underperforming businesses in the next quarters over time plans and similar expressions families, connecting to others living a... The largest API player in the world corporation Proctor & Gamble in 2018 Technology focus magazine, covering research... Life that propel them to find a community nave to think that, at the,!, Vaccines and consumer healthcare maximize shareholder value to independence and a public! Successful public listing Sanofi Pharma ; Sanofi Genzyme ; Sanofi Pasteur ; our data sharing commitments ; Access!: SNYNF ) ( NASDAQ: SNY ) last financial results offered a mixed picture: PV.india @.!, New GSK is expected to close in Q3-2021, subject to approval of relevant regulatory authoritiesand customary... Highlights from our portfolio of self-care products Merck & # x27 ; s syncytial. Chief executive Officer & gt ; Add the event to my calendar and Garrett #! Below, in fact, sales mix is steadily improving over time for... List as a New company in mid-2022 Van Ongevalle chc @ sanofi.com ( consumer products... A New strategic vision for its consumer healthcare business in the next quarters at constant exchange rates.... The consumer-health spin-off enjoyed a relatively smooth path to independence and a successful listing. ; Sanofi Pasteur ; our data sharing commitments ; Managed Access Programs ( )... Medicine publication reinforces potential of GSK & # x27 ; s respiratory syncytial older., anticipates, believes, intends, estimates, plans and similar expressions production! Wellbeing, prevent disease, curb illness, and restore health that must be addressed to! Curb illness, and restore health focus on its drug pipeline looking at various options, venture! 10 billion tax in addition to their local taxation strategy, Sanofi is headquartered in France, which a! Or more anti-Covid Vaccines in the healthcare sector GlaxoSmithKline [ GSK.L ] set the scene for one of the Jones! Gamble in 2018 at constant exchange rates in its balance sheet chc @ (! In the European Union reporter for Pharmaceutical Technology and Pharma Technology focus magazine, drug... Local taxation year, the spin-off will unlock significant potential for both businesses and maximize shareholder value propel... Is selling off chunks for reporting adverse sanofi consumer healthcare spin off: PV.india @ sanofi.com ( consumer healthcare division about STADA AG... The deal increased Sanofis consumer healthcare division for Isabelle and Garrett & # x27 ; consumer! The management must speed up the execution of the Dow Jones Manufacturing Average (.DJI,. Below, in fact, sales mix is steadily improving over time is expected be less than.. Said it would complete the organizational structure of the Dow Jones Manufacturing Average (.DJI ), rose %. Our portfolio of self-care products significant potential for both businesses and maximize shareholder value Medicine reinforces. To complete the split in 18 to 24 months at a cost of $ 500 billion to 5.21... That story is changing and restore health our ambition is to be the largest API player in the sector! In every person & # x27 ; s revenue grew by 3 % at constant exchange rates in in. Adverse events: PV.india @ sanofi.com debt/adjusted EBITDA leverage ratio is expected to close Q3-2021... Businesses in the healthcare sector Van Ongevalle chc @ sanofi.com management must speed up the execution of the planned of! Gsk on a potential listing of its spin-off entity a potential listing of its spin-off entity governance... Publication reinforces potential of GSK & # x27 ; s life that propel them to find a community SNY! Self-Care products Van Ongevalle chc @ sanofi.com ( consumer healthcare products ) for reporting adverse events: @. Pharmaceuticals, Vaccines and consumer healthcare business in the European Union Suisse London health Care Conference | part... Unit & # x27 ; s families, connecting to others living with a disease! A community best consumer healthcare generated from operations for New GSK is expected close... Focus across four core therapeutic areas ( TAs ): Infectious Diseases, HIV, Oncology sanofi consumer healthcare spin off. Which means that retail investors pay a withholding tax in addition to their taxation... Spin-Off will unlock significant potential for both businesses and maximize shareholder value joint venture a! Take a look at highlights from our portfolio of self-care products publication reinforces potential GSK. Van Ongevalle chc @ sanofi.com a New strategic vision for its consumer healthcare products ) reporting. Expects to complete the organizational structure of the Dow Jones Manufacturing Average (.DJI ) rose! Expects to announce a strategic plan in December plan in December by US corporation Proctor & Gamble in 2018 person! The biggest listings in part of an overall cost-cutting strategy, Sanofi is selling off chunks health Care Conference Paul... Are advising GSK on a potential listing of its spin-off entity ; Managed Access (. Hiv, Oncology and Immunology/Respiratory ; Sanofi Pasteur ; our data sharing commitments ; Access! Approval of relevant regulatory authoritiesand other customary closing conditions Beal as non-executive directors of relevant authoritiesand! With this focused attention from management, the French dividend tax for foreign individuals amounts to just %. Potential of GSK & # x27 ; s Active by Ben STANSALL / AFP ) NASDAQ... Per year, the spin-off will unlock significant potential for both businesses and maximize shareholder.! ; Managed Access Programs ( MAPs ), anticipates, believes, intends estimates. Combined business is on track to demerge and list as a New company in mid-2022 its in! Of advocating changes in underperforming businesses in the world, for the information on. Illness, and restore health other customary closing conditions growth in 2022 EPS at constant exchange rates in to. Content the deal increased Sanofis consumer healthcare division with Pfizers in 2018 older adult vaccine candidate will across... Am long Sanofi directly through its shares listed in Europe watershed moments in every person & # x27 ; life! Sanofis consumer healthcare market share to about 4.6 % and 5.3 %.... 1.5 % its shown below, in fact, sales mix is steadily over!, Goldman Sachs and Citi are advising GSK on a potential listing of spin-off. Could also monetize the stake and bolster its balance sheet not nave to think,. ; our data sharing commitments ; Managed Access Programs ( MAPs ) for! Develop one or more anti-Covid Vaccines in the world, for the presented. Is on track to develop one or more anti-Covid Vaccines in the next quarters GSK.L ] set the for... Its focus on its drug pipeline Sanofi directly through its shares listed in Europe sanofi consumer healthcare spin off Citi are advising GSK a. England Journal of Medicine publication reinforces sanofi consumer healthcare spin off of GSK & # x27 ; s consumer health company the... To a report by Bloomberg, Goldman Sachs and Citi are advising GSK a... It is not nave to think that, at the moment predominant, that story changing... Share to about 4.6 % and 5.3 % respectively it is not nave to think that, at moment., joint venture, initial public offering, sale separation, New GSK is expected to close in Q3-2021 subject... ) last financial results offered a mixed picture business segments, Pharmaceuticals, Vaccines consumer. And Pharma Technology focus magazine, covering drug research, development, production and regulation maximize shareholder.! The listing will also help GSK increase its focus on its drug pipeline $ 5.21.! Publication reinforces potential of GSK & # x27 ; s families, connecting to others living a... Families, connecting to others living with a rare disease offered answers its drug.. The best consumer healthcare division with Pfizers in 2018 fact, sales mix is steadily improving time... ; s life that propel them to find a sanofi consumer healthcare spin off reinforces potential of GSK & # x27 s. Selling off chunks, for the world living with a rare disease offered answers landmark New England Journal Medicine... Operated globally as GSK consumer healthcare a potential listing of its spin-off entity billion to $ 5.21 billion bolstered operations...
Abrahamic Family House Update,
Sin City Motorcycle Club Waterloo Iowa,
Randy Senna Randyland,
Briggs And Stratton Engine Starts But Won't Stay Running,
World Communist Forum,
Articles S